PanGIA Biotech, a company advancing urine-based ... using urine-based liquid biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics ...

Inc., a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies for cancer treatment, announced that an abstract has been accepted for poster presentation ...

Adagene Inc. announced a poster presentation for the ASCO 2025 conference ... which can enhance visibility and credibility within the biotechnology community. The updated results of the Phase ...

May 06, 2025--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging ... today announced that three posters were presented at IMMUNOLOGY2025, the annual ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek ...

today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc., and Genetics Institute of America has been accepted for presentation at the 2025 Annual Meeting of ...

--(BUSINESS WIRE)--#ASCO--PanGIA Biotech, a company advancing urine-based ... using urine-based liquid biopsy (Abstract #3080), has been accepted for presentation in the poster session titled ...